CN108938604A - Compound formula mannitol injection liquid - Google Patents
Compound formula mannitol injection liquid Download PDFInfo
- Publication number
- CN108938604A CN108938604A CN201710361142.4A CN201710361142A CN108938604A CN 108938604 A CN108938604 A CN 108938604A CN 201710361142 A CN201710361142 A CN 201710361142A CN 108938604 A CN108938604 A CN 108938604A
- Authority
- CN
- China
- Prior art keywords
- mannitol
- injection liquid
- formula
- weight
- sorbierite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A kind of compound formula mannitol injection liquid, which is characterized in that be made of formula as below: 5% ~ 18% weight of mannitol；20% ~ 2% weight of sorbierite；Water for injection, surplus.The present invention relates to a kind of formulas of medical compound formula mannitol injection liquid.The formula includes simultaneously mannitol and sorbierite.The compound formula mannitol injection liquid does not have crystallization when room temperature is lower and is precipitated, and solves the crystallisation problems of formula mannitol injection liquid, is that a kind of clinical use is convenient, the ideal mannitol formulations that adverse reaction is few.
Description
Technical field
The present invention relates to a kind of medical fields, and in particular to a kind of formula of compound formula mannitol injection liquid.The formula
It simultaneously include mannitol and sorbierite.The compound formula mannitol injection liquid does not have crystallization when room temperature is lower and is precipitated, and solves sweet
The crystallisation problems for revealing alcohol injection are that a kind of clinical use is convenient, the ideal mannitol formulations that adverse reaction is few.
Background technique
20% formula mannitol injection liquid is widely used in facing for neurosurgery as intracranial pressure and free radical scavenger is reduced
Bed.Currently, treatment brain edema, reduction intracranial pressure, mannitol is preferred, reduction intracranial pressure significant effect, " is bounced existing without obvious
As ".Due to 20% mannitol solution system supersaturated solution, during clinical use, the crystallization of formula mannitol injection liquid is to clinic
Using big inconvenience is brought, when room temperature is lower than 15 DEG C, crystallization is precipitated in mannitol more, cannot be used immediately, be needed to tie
Crystalline substance can be injected intravenously after dissolving, time-consuming and laborious.In addition, some crystallizations are in invisible fine particles, in such case
Lower use will lead to the adverse consequences such as infusion reaction.
Sorbierite is the isomer of mannitol, and effect, purposes are similar to mannitol, but sorbierite part in vivo
It converting and loses hypertonic effect, effect is weak compared with mannitol, however on the other hand, sorbierite is bigger than mannitol solubility.Therefore,
The present invention intends solving the above problems, and is made into compound formula mannitol, to reduce the crystallization of mannitol and reduce the bad anti-of mannitol
It answers.
Summary of the invention
The present invention provides a kind of medical compound formula mannitol injection liquid, and the purpose is to be used to substitute existing medical mannitol injection
Liquid is easy crystallization precipitation to solve current formula mannitol injection liquid at low ambient temperatures, leads to infusion reaction etc. (when room temperature is lower)
The problem of adverse consequences, provides conveniently for clinical use.
In order to achieve the above objectives, the technical solution adopted by the present invention is that: a kind of compound formula mannitol injection liquid, by formula as below
Composition:
5%~18% weight of mannitol；
20%~2% weight of sorbierite；
Water for injection surplus.
Related content in above-mentioned technical proposal is explained as follows:
1, in above scheme, preferable content range in the formula are as follows:
10%~18% weight of mannitol；
12.5%~2.5% weight of sorbierite；
Water for injection surplus.
2. in above scheme, optimum content range in the formula are as follows:
15%~18% weight of mannitol；
6.25%~2.5% weight of sorbierite；
Water for injection surplus.
3, mechanism of the invention
In order to solve the problems, such as crystallization of mannitol, suitably reduction mannitol concentration, and osmotic pressure does not reduce, and same point of mannitol is added
Isomers sorbierite reduces mannitol concentration because the solubility of sorbierite is bigger than mannitol, increases sorbitol concentration,
Osmotic pressure is constant to reach, and which reduces the crystallization of mannitol precipitations, solves clinical use inconvenience, at the same reduce due to
Adverse reaction caused by particle.
Since above scheme is used, the present invention has following advantages and effect compared with prior art:
1, advantage: (1), clinical use it is convenient；(2), the adverse reactions such as infusion reaction are reduced.
2, mannitol effect: is prepared respectively: sorbierite (5%:18.75%；10%:12.5%；15%:6.25%；
18%:2.5%) the compound formula mannitol solution 250ml of four kinds of specifications set 2~8 DEG C of refrigerators after 24 hours, and feelings are precipitated in observation crystallization
Condition, as a result first three specification nodeless mesh is precipitated, and finally a kind of specification has a small amount of crystallization.
Specific embodiment
The present invention will be further described below with reference to examples:
Embodiment one:
(1), it is formulated
10% weight of mannitol；
12.5% weight of sorbierite；
Water for injection surplus.
(2), preparation method
Routinely mannitol production method.The conventional mannitol production method refers to 20% mannitol note described in the prior art
Penetrate the production method of liquid.
Embodiment two:
(1), it is formulated
15% weight of mannitol；
6.25% weight of sorbierite；
Water for injection surplus.
(2), preparation method
Routinely mannitol production method.The conventional mannitol production method refers to 20% mannitol note described in the prior art
Penetrate the production method of liquid.
Embodiment three:
(1), it is formulated
16% weight of mannitol；
5% weight of sorbierite；
Water for injection surplus.
(2), preparation method
Routinely mannitol production method, the conventional mannitol production method refer to 20% mannitol note described in the prior art
Penetrate the production method of liquid.
The above embodiments merely illustrate the technical concept and features of the present invention, and its object is to allow person skilled in the art
Scholar cans understand the content of the present invention and implement it accordingly, and it is not intended to limit the scope of the present invention.It is all according to the present invention
Equivalent change or modification made by Spirit Essence, should be covered by the protection scope of the present invention.
Claims (3)
1. a kind of compound formula mannitol injection liquid, which is characterized in that be made of formula as below:
5%~18% weight of mannitol；
20%~2% weight of sorbierite；
Water for injection surplus.
2. compound formula mannitol injection liquid according to claim 1, it is characterised in that: preferable content range in the formula
Are as follows:
10%~18% weight of mannitol；
12.5%~2.5% weight of sorbierite；
Water for injection surplus.
3. compound formula mannitol injection liquid according to claim 1, it is characterised in that: optimum content range in the formula
Are as follows:
15%~18% weight of mannitol；
6.25%~2.5% weight of sorbierite；
Water for injection surplus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710361142.4A CN108938604A (en) | 2017-05-22 | 2017-05-22 | Compound formula mannitol injection liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710361142.4A CN108938604A (en) | 2017-05-22 | 2017-05-22 | Compound formula mannitol injection liquid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108938604A true CN108938604A (en) | 2018-12-07 |
Family
ID=64462201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710361142.4A Pending CN108938604A (en) | 2017-05-22 | 2017-05-22 | Compound formula mannitol injection liquid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108938604A (en) |
-
2017
- 2017-05-22 CN CN201710361142.4A patent/CN108938604A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500570A (en) | Co-solvent compositions and methods for improving delivery of dantrolene therapeutics | |
| CN102008490B (en) | Compound florfenicol injection for animal | |
| CN101439180A (en) | Medicament composition for improving stability of Ulinastatin | |
| CN105001289A (en) | Eprinomectin refining method | |
| CN101884638A (en) | Application of 5alpha-androstane-3beta,5,6beta-triol in preparing neuro-protective medicaments | |
| US5286856A (en) | Production of crystalline penem | |
| CN109953942A (en) | Compound formula mannitol injection liquid | |
| CN108938604A (en) | Compound formula mannitol injection liquid | |
| CN103315999A (en) | Compound amino acid composition and preparation method thereof | |
| CN102145009A (en) | Octadeca compound amino acid injection and preparation method thereof | |
| CN106389353A (en) | Compound ammonium glycyrrhetate S for injection, and preparation method therefor | |
| US20100184715A1 (en) | Stable salts of s-adenosylmethionine and process for the preparation thereof | |
| WO2016005995A2 (en) | Glycol free stable liquid compositions of bendamustine | |
| CN106511324A (en) | Compound mannitol injection | |
| CN101985444A (en) | V crystal form of Fasudil hydrochloride and preparation method and application thereof | |
| US5972912A (en) | Method for lyophilizing ifosfamide | |
| CN102718693B (en) | Carbazochrome sodium sulfonate compound and composition thereof | |
| CN103432086B (en) | Pemetrexed disodium freeze-dried powder injection for injection and preparation method thereof | |
| CN102657677B (en) | Glycerin fructose sodium chloride injection | |
| CN103417474B (en) | Calcium dibutyacyladenosine cyclophosphate-containing composition for injection | |
| WO2016199053A1 (en) | Stable liquid formulations of pemetrexed | |
| CN102188437A (en) | Glycerol fructose injection and preparation method thereof | |
| CN102757471A (en) | Novel active cytidine disodium triphosphate compound and pharmaceutical composition thereof | |
| CN104027305A (en) | Mannitol injection | |
| TW200526230A (en) | Frozen-dried preparation containing prostaglandin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181207 |
|
| WD01 | Invention patent application deemed withdrawn after publication |